Compositions and methods for treating arenavirus infection
AssigneesChildren's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
InventorsJonathan Abraham, Stephen Harrison, Kai Wucherpfennig
Life of this patent
Estimating the term…
Abstract
The invention generally provides compositions and methods of treating or preventing an arenavirus infection, using an agent that inhibits binding of an arenavirus glycoprotein 1 (GP1) polypeptide to transferrin receptor 1 (TfR1). The invention also provides methods of designing or identifying therapeutic agents that bind to or target a GP1 receptor-binding site (RBS) to inhibit arenavirus attachment to a cell, and therapeutic agents identified using the methods.
Claims19
An isolated antibody or an antigen-binding fragment thereof that specifically binds to arenavirus glycoprotein 1 (GP1), wherein the antibody or the antigen binding fragment thereof comprises a heavy chain comprising three complementary determining region (CDR) sequences as follows:
- CDR H1 sequence
- (SEQ ID NO:
- 1)
- GFTFGTSI
- CDR H2 sequence
- (SEQ ID NO:
- 2)
- ISHDESRK
- CDR H3 sequence
- (SEQ ID NO:
- 3)
- AKDLSPPYSYAWDIFQYW
- and a light chain comprising three CDR sequences as follows:
- CDR L1 sequence
- (SEQ ID NO:
- 4)
- QSVLYSSRSDNKY
- CDR L2 sequence
- (SEQ ID NO:
- 36)
- WAS
- CDR L3 sequence
- (SEQ ID NO:
- 5)
- QQYYSSPPTF;
- or
- wherein the antibody or the antigen binding fragment thereof comprises a heavy chain comprising three CDR sequences as follows:
- CDR H1 sequence
- (SEQ ID NO:
- 6)
- GFTFSSA
- CDR H2 sequence
- (SEQ ID NO:
- 7)
- IWSDGSNE
- CDR H3 sequence
- (SEQ ID NO:
- 8)
- ATDKTYVSGYTSTWYYFNY
- and a light chain comprising three CDR sequences as follows:
- CDR L1 sequence
- (SEQ ID NO:
- 9)
- QSIDNW
- CDR L2 sequence
- (SEQ ID NO:
- 37)
- KAS;
- and
- CDR L3 sequence
- (SEQ ID NO:
- 10)
- QHRT.
Dependencies are inferred from the claim text.